CONTEXT THERAPEUTICS INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
CONTEXT THERAPEUTICS INC. (CNTX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $528.10 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- CONTEXT THERAPEUTICS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $528.10K, a 35.72% increase year-over-year.
- CONTEXT THERAPEUTICS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $409.22K, a 39.32% increase year-over-year.
- CONTEXT THERAPEUTICS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $323.08K, a 51.68% increase year-over-year.
- CONTEXT THERAPEUTICS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $389.11K, a 147.78% increase year-over-year.
- CONTEXT THERAPEUTICS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $1.33M, a 58.11% increase from fiscal 2024.
- CONTEXT THERAPEUTICS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $841.87K, a 21.82% decline from fiscal 2023.
- CONTEXT THERAPEUTICS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.08M, a 10.28% increase from fiscal 2022.
- CONTEXT THERAPEUTICS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $976.44K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $528.10K 10-Q · filed 2026-08-05 | $937.32K derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $409.22K 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $1.33M 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $323.08K 10-Q · filed 2025-11-05 | $712.20K derived: sum of 2 quarters · filed 2026-08-05 | $1.01M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-06-30 | $389.11K 10-Q · filed 2026-08-05 | $682.83K derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $293.72K 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $841.87K 10-K · filed 2026-03-23 | |||
| 2024-09-30 | $213.00K 10-Q · filed 2025-11-05 | $370.04K derived: sum of 2 quarters · filed 2025-11-05 | $610.05K derived: sum of 3 quarters · filed 2025-11-05 | |
| 2024-06-30 | $157.04K 10-Q · filed 2025-11-05 | $397.04K derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2024-03-31 | $240.01K 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $1.08M 10-K · filed 2025-03-20 | |||
| 2023-09-30 | $254.95K 10-Q · filed 2024-11-06 | $538.05K derived: sum of 2 quarters · filed 2024-11-06 | $820.81K derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | $283.10K 10-Q · filed 2024-11-06 | $565.87K derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | $282.76K 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $976.44K 10-K · filed 2024-03-21 | |||
| 2022-09-30 | $276.52K 10-Q · filed 2023-11-09 | $517.85K derived: sum of 2 quarters · filed 2023-11-09 | $732.80K derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $241.32K 10-Q · filed 2023-11-09 | $456.28K derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $214.96K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |